Condition: Cancer · Advanced Cancer · Locally Advanced Carcinoma · Sponsor: Angiex, Inc.
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and will receive two safety follow-up telephone contacts up to 90 days following the last dose of study drug.
This description comes directly from the study's public registry record.
Glen Weiss, MD · 857-203-7808 · trials@angiex.com
Always discuss trial participation with your own doctor first.
| USC/Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Florida Cancer Specialist | Sarasota, Florida, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Sarah Cannon Research Center | Nashville, Tennessee, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| NEXT Oncology | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06440005